ERBB2 and breast carcinoma: Accordingly, only a minority of HR+, HER2− patients appears to benefit from CT: in a large meta-analysis performed by the Early Breast Cancer Trialists’ Collaborative Group, the reduction of the 10-year recurrence rate by adjuvant CT was <10%5.